Pulmonary TB
13
1
2
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
15%
2 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (13)
Xpert MTB/RIF Ultra Trial
Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease
Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults
Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.
Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
Promoting Overall Care and Management Related to Tuberculosis Infection Through Pharmaceutical Care and Text Messaging
Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
Performance Evaluation of TB Breath- and Cough-testing Platforms
Comparison Between Two Strategies for the Diagnosis of TB
Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb